SCHEMBL6034569

SCHEMBL6034569

CC(C)c1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1nn(C2CCCCC2)cc1CC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
GCG P01275 3/20 0.34
HRH3 Q9Y5N1 3/20 0.34
ACACB O00763 1/20 0.34
DGAT1 O75907 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
HDAC4 P56524 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 2/20 0.32
S100A4 P26447 1/20 0.32
TIPARP Q7Z3E1 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ABL1 P00519 1/20 0.32
PTGES O14684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6036262 0.89 PPARD (0.37) PPARDPPARAL3MBTL1GCGDGAT1
SCHEMBL1632906 0.86 GCGR (0.34) PPARDL3MBTL1GCGHRH3ACACB
SCHEMBL6036015 0.84 GCGR (0.35) PPARDPPARAL3MBTL1GCGHRH3
SCHEMBL6035747 0.82 KDM4E (0.36) PPARDPPARAL3MBTL1HRH3DGAT1
SCHEMBL6036211 0.80 GCG (0.35) PPARDPPARAL3MBTL1GCGHRH3
SCHEMBL6036245 0.80 PPARD (0.42) PPARDPPARAL3MBTL1HDAC4SMN1; SMN2
SCHEMBL6035328 0.80 HDAC4 (0.42) L3MBTL1HRH3ACACBHDAC4SMN1; SMN2
SCHEMBL6034602 0.79 PTGDR2 (0.38) PPARDPPARAL3MBTL1GCGHCRTR1
SCHEMBL6035628 0.79 GCGR (0.37) L3MBTL1GCGHRH3ACACBHCRTR1
SCHEMBL6035589 0.79 GCGR (0.36) L3MBTL1GCGHRH3ACACBHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PPARD 2488/4885PPARA 1717/4885L3MBTL1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.